Result of General Meeting
("Renalytix" or the "Company")
Result of General Meeting
The results of the
|
Resolution |
In Favour Votes |
% |
|
Against Votes |
% |
|
Withheld Votes |
|
1 |
35,540,650 |
98.8% |
|
439,984 |
1.2% |
|
62,458 |
|
2 |
35,509,132 |
98.7% |
|
471,662 |
1.3% |
|
62,298 |
For further information, please contact:
|
|
|
|
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07407 804 654 / 07584 391 303 |
|
|
|
|
|
|
|
|
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the